Ketamine With Psychotherapy for the Treatment of Depression
Fernando Espí Forcén, Maren Nyer
Psychiatric Annals September 1, 2022 DOI: 10.3928/00485713-20220810-04 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Key findings | The article reviews literature on the potential benefits of combining ketamine with psychotherapy versus ketamine alone for psychiatric disorders. |
Abstract
To date, ketamine is the only prescribable psychedelic medicine in the United States. Ketamine is also one of the most promising drugs for the treatment of depression. In the current paradigm of care, most ketamine clinics in the United States treat patients with mood disorders with ketamine and its derivatives alone without psychotherapy. The purpose of this article is to review the most recent literature about ketamine and psychotherapy for the treatment of psychiatric disorders and reflect and open a discussion about the potential benefits of combined ketamine treatment with psychotherapy versus ketamine alone. [ Psychiatr Ann. 2022;52(9):371–374.]
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |